[Secondary prevention of myocardial infarct. A new anticoagulant improves survival prospects].
Dirk
D
Einecke
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D003328:Coronary Thrombosis / Q000188:drug therapy* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D018570:Risk Assessment; D000069552:Rivaroxaban; D055502:Secondary Prevention; D015996:Survival Rate; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban